[Etidronate and calcitonin to PTH (1-84) in postmenopausal osteoporosis]. 2011

Luis Pablo Rodríguez Rodríguez

Postmenopausal osteoporosis is now a major health problem. The advancement of knowledge on the role preferred cellular osteocytes, osteoblasts and osteoclasts in bone tissue, the biochemical activity and gene expression, interaction with physical activity, diet and nutritional measures, as well as various currently available drugs are disclosed in interaction with clinical studies of etidronate and calcitonin, parathyroid hormone and recombinant 1-84. It is concluded in relation to its activity at eighteen months of the administration and its assessment by bone mineral density, biochemical markers and production of fractures.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010281 Parathyroid Hormone A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. Natpara,PTH (1-84),PTH(1-34),Parathormone,Parathyrin,Parathyroid Hormone (1-34),Parathyroid Hormone (1-84),Parathyroid Hormone Peptide (1-34),Hormone, Parathyroid
D002116 Calcitonin A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults. Thyrocalcitonin,Calcitonin(1-32),Calcitrin,Ciba 47175-BA,Eel Calcitonin,Calcitonin, Eel,Ciba 47175 BA,Ciba 47175BA
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012968 Etidronic Acid A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover. EHDP,Ethanehydroxydiphosphonate,Etidronate,Etidronate Disodium,Sodium Etidronate,(1-hydroxyethylene)diphosphonic acid,(1-hydroxyethylene)diphosphonic acid, Tetrapotassium Salt,1,1-hydroxyethylenediphosphonate,1-Hydroxyethane-1,1-Diphosphonate,1-Hydroxyethylidene-1,1-Bisphosphonate,Dicalcium EHDP,Dicalcium Etidronate,Didronel,Disodium 1-Hydroxyethylene Diphosphonate,Disodium Etidronate,Ethanehydroxyphosphate,Etidronate, Tetrapotassium Salt,HEDP,HEDSPA,Hydroxyethanediphosphonate,Hydroxyethylidene Diphosphonic Acid,Phosphonic acid, (1-hydroxyethylidene)bis-, disodium salt,Xidifon,Xidiphon,Xydiphone,1 Hydroxyethane 1,1 Diphosphonate,1 Hydroxyethylidene 1,1 Bisphosphonate,1,1 hydroxyethylenediphosphonate,1-Hydroxyethylene Diphosphonate, Disodium,Diphosphonate, Disodium 1-Hydroxyethylene,Diphosphonic Acid, Hydroxyethylidene,Disodium 1 Hydroxyethylene Diphosphonate,EHDP, Dicalcium,Etidronate, Dicalcium,Etidronate, Disodium,Etidronate, Sodium,Salt Etidronate, Tetrapotassium,Tetrapotassium Salt Etidronate
D015663 Osteoporosis, Postmenopausal Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency. Bone Loss, Perimenopausal,Bone Loss, Postmenopausal,Perimenopausal Bone Loss,Postmenopausal Bone Loss,Postmenopausal Osteoporosis,Osteoporosis, Post-Menopausal,Bone Losses, Perimenopausal,Bone Losses, Postmenopausal,Osteoporoses, Post-Menopausal,Osteoporoses, Postmenopausal,Osteoporosis, Post Menopausal,Perimenopausal Bone Losses,Post-Menopausal Osteoporoses,Post-Menopausal Osteoporosis,Postmenopausal Bone Losses,Postmenopausal Osteoporoses
D050071 Bone Density Conservation Agents Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. Antiresorptive Agent,Antiresorptive Agents,Antiresorptive Drugs,Bone Resorption Inhibitors,Bone Resorption Inhibitory Agents,Agent, Antiresorptive,Inhibitors, Bone Resorption,Resorption Inhibitors, Bone

Related Publications

Luis Pablo Rodríguez Rodríguez
January 2010, Journal of medical economics,
Luis Pablo Rodríguez Rodríguez
December 1990, The Medical letter on drugs and therapeutics,
Luis Pablo Rodríguez Rodríguez
October 1990, The New England journal of medicine,
Luis Pablo Rodríguez Rodríguez
November 1976, Clinical pharmacology and therapeutics,
Luis Pablo Rodríguez Rodríguez
November 2008, Current medical research and opinion,
Luis Pablo Rodríguez Rodríguez
November 2010, Current medical research and opinion,
Luis Pablo Rodríguez Rodríguez
March 1999, Minerva medica,
Luis Pablo Rodríguez Rodríguez
October 1993, The Annals of pharmacotherapy,
Luis Pablo Rodríguez Rodríguez
January 1984, Clinical endocrinology,
Luis Pablo Rodríguez Rodríguez
January 2001, The Cochrane database of systematic reviews,
Copied contents to your clipboard!